Biosortia Pharmaceuticals Inc., a biopharma company that recently moved to San Diego from Ohio, has launched three new oncology research projects.
The projects will investigate potential drug discovery in pediatric cancer, liver cancer (hepatitis C virus) and an alternative approach to combat tumor growth by stimulating a patient's immune responses (immuno-oncology). The immune response strategy can have application across a range of cancer targets including pancreatic cancer, liver cancer, myeloma, neuroblastoma and ovarian cancer, the company said in a statement.
The research will be conducted by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and The Research Institute at Nationwide Children's Hospital in collaboration with Biosortia.
Biosortia already has existing drug development anti-cancer programs, as well as programs relating to autoimmune and cardiovascular